Johnson & Johnson
US healthcare group whose MedTech arm develops the Ottava soft-tissue surgical robot and the Monarch endoluminal platform.
- Intuitive places 468 da Vinci robots as upgrades to da Vinci 5 accelerate, and raises its margin outlook for a second time
Intuitive placed 468 da Vinci systems in the second quarter of 2026, up from 395 a year earlier, including 246 da Vinci 5 units, and revenue rose 19% to $2.89 billion, the company said on 16 July. It lifted its 2026 non-GAAP gross margin outlook to 68% to 69% of revenue, the second increase this year, while holding da Vinci procedure growth guidance at 13.5% to 15.5% and pointing to the midpoint.
Mentioned - Johnson & Johnson files Ottava surgical robot with the FDA, seeking a De Novo route into general surgery
Johnson & Johnson has submitted its Ottava soft-tissue surgical robot to the US Food and Drug Administration in a De Novo classification request covering several upper abdominal procedures, backed by a 32-patient gastric bypass study at six US hospitals. The filing comes weeks after Medtronic and CMR Surgical won US clearances, widening the field challenging Intuitive's 10,763-system da Vinci base.
Subject - Distalmotion raises US$150 million to take its DEXTER surgical robot into US outpatient centres
Swiss surgical robot maker Distalmotion closed a US$150 million Series G led by Revival Healthcare Capital on 18 November 2025 and named former Silk Road Medical chief executive Chas McKhann executive chairman. Johnson & Johnson's venture arm followed with a strategic investment in January 2026, and by August the FDA had cleared DEXTER for five procedures aimed at ambulatory surgery centres.
investor